Target Name: MIR550A1
NCBI ID: G693133
Review Report on MIR550A1 Target / Biomarker Content of Review Report on MIR550A1 Target / Biomarker
MIR550A1
Other Name(s): hsa-miR-550a-3p | hsa-miR-550a-5p | microRNA 550a-1 | MIR550-1 | hsa-mir-550a-1 | mir-550a-1 | MicroRNA 550a-1 | MIRN550-1

MIR550A1: A Potential Drug Target and Biomarker for Diseases

MIR550A1 (hsa-miR-550a-3p) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study.

MIR550A1 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. miRNAs are designed to target specific mRNAs for degradation, and their levels are regulated by various factors, including translation efficiency, cleavage by enzymes, and interactions with other molecules.

The hsa-miR-550a-3p molecule has a unique structure, with a length of 20.9 nucleotides and a 19.6-nt stem-loop region. The stem-loop region is a common structural element in miRNAs and is responsible for maintaining the stability of the molecule. The hsa-miR-550a-3p molecule also has a unique expression pattern, with high levels of expression in the liver and moderate levels of expression in the heart, brain, and other tissues.

The hsa-miR-550a-3p molecule has been shown to have various biological functions, including regulating gene expression, cell survival, and cellular processes. For example, studies have shown that hsa-miR-550a-3p can promote the expression of target genes involved in cell growth, apoptosis, and inflammation. It has also been shown to play a role in the regulation of cellular processes, including cell cycle progression, cell migration, and tissue repair.

One of the most promising aspects of hsa-miR-550a-3p is its potential as a drug target. The high levels of expression in the liver and moderate levels of expression in other tissues make it an attractive target for drugs that are designed to modulate miRNA levels or prevent the deregulation of miRNAs. Studies have shown that hsa-miR-550a-3p can be effectively targeted with small molecules, including inhibitors of the miRNA-protein interaction, and that these inhibitors can significantly reduce hsa-miR-550a-3p levels in various tissues.

In addition to its potential as a drug target, hsa-miR-550a-3p has also been shown to be a valuable biomarker for various diseases. The unique expression pattern of hsa-miR-550a-3p makes it an attractive target for diagnostic assays, including qRT-PCR, RNAseq, and western blotting. Studies have shown that hsa-miR-550a-3p levels are significantly altered in various diseases, including cancer, and that these changes can be used as biomarkers for disease diagnosis and monitoring.

In conclusion, hsa-miR-550a-3p is a non-coding RNA molecule that has a unique structure and expression pattern. Its high levels of expression in the liver and moderate levels of expression in other tissues make it an attractive target for drugs that are designed to modulate miRNA levels or prevent the deregulation of miRNAs. Studies have also shown that hsa-miR-550a-3p can be effectively targeted with small molecules and can be used as a valuable biomarker for various diseases. Further research is needed to fully understand the role of hsa-miR-550a-3p in biology and to develop effective drugs that can target this molecule.

Protein Name: MicroRNA 550a-1

The "MIR550A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR550A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR550A2 | MIR550A3 | MIR550B1 | MIR550B2 | MIR551A | MIR551B | MIR552 | MIR553 | MIR554 | MIR555 | MIR556 | MIR557 | MIR5571 | MIR5572 | MIR5579 | MIR558 | MIR5580 | MIR5581 | MIR5582 | MIR5583-1 | MIR5584 | MIR5585 | MIR5586 | MIR5587 | MIR5588 | MIR5589 | MIR559 | MIR5590 | MIR5591 | MIR561 | MIR562 | MIR563 | MIR564 | MIR566 | MIR567 | MIR568 | MIR5680 | MIR5681A | MIR5681B | MIR5682 | MIR5683 | MIR5684 | MIR5685 | MIR5687 | MIR5688 | MIR5689 | MIR569 | MIR5690 | MIR5691 | MIR5692A1 | MIR5692A2 | MIR5692B | MIR5692C1 | MIR5692C2 | MIR5693 | MIR5694 | MIR5695 | MIR5696 | MIR5697 | MIR5698 | MIR5699 | MIR570 | MIR5700 | MIR5701-1 | MIR5701-2 | MIR5701-3 | MIR5702 | MIR5703 | MIR5704 | MIR5705 | MIR5706 | MIR5707 | MIR5708 | MIR570HG | MIR571 | MIR572 | MIR573 | MIR5739 | MIR574 | MIR575 | MIR576 | MIR577 | MIR578 | MIR5787 | MIR579 | MIR580 | MIR581 | MIR582 | MIR583 | MIR584 | MIR585 | MIR586 | MIR587 | MIR588 | MIR589 | MIR590 | MIR591 | MIR592 | MIR593 | MIR595